Genenta Science SPA
NASDAQ:GNTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genenta Science SPA
Income from Continuing Operations
Genenta Science SPA
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genenta Science SPA
NASDAQ:GNTA
|
Income from Continuing Operations
-€6.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Philogen SpA
MIL:PHIL
|
Income from Continuing Operations
€45.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
100%
|
CAGR 10-Years
N/A
|
|
|
Ulisse Biomed Spa
MIL:UBM
|
Income from Continuing Operations
-€5.9m
|
CAGR 3-Years
-114%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
Genenta Science SPA
Glance View
Genenta Science SpA engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. The company is headquartered in Milan, Milano and currently employs 4 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
See Also
What is Genenta Science SPA's Income from Continuing Operations?
Income from Continuing Operations
-6.5m
EUR
Based on the financial report for Dec 31, 2025, Genenta Science SPA's Income from Continuing Operations amounts to -6.5m EUR.
What is Genenta Science SPA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-3%
Over the last year, the Income from Continuing Operations growth was 27%. The average annual Income from Continuing Operations growth rates for Genenta Science SPA have been 8% over the past three years , -3% over the past five years .
